Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.

Tai-Jan ChiuYung-Yeh SuShih-Hung YangChung-Pin LiLi-Yuan BaiNai-Jung ChiangShih-Chang ChuangYan-Shen ShanDe-Chuan ChanLi-Tzong ChenChia-Jui YenCheng-Ming PengYen-Yang ChenJen-Shi ChenWen-Chi Chou

Published in: Therapeutic advances in medical oncology (2021)

Our results support the use of nal-IRI + 5-FU/LV as standard clinical practice for treating patients with PDAC based on this large population-based study. Our findings encourage physicians to provide adequate doses of nal-IRI in order to achieve better outcomes without compromising safety profiles.

Keyphrases

clinical practice
end stage renal disease
chronic kidney disease
newly diagnosed
primary care
prognostic factors
type diabetes
skeletal muscle
patient reported outcomes
insulin resistance